Digital Diagnostics is a pioneering AI diagnostics company on a mission to transform the quality, accessibility and affordability of healthcare. Founded and led by Dr. Michael Abramoff, an ophthalmologist, neuroscientist and computer engineer, Digital Diagnostics developed a patented biomarker-based approach to build autonomous algorithms that make clinical decisions without human intervention. Digital Diagnostics and its flagship product IDx-DR, an autonomous AI system FDA-authorized to diagnose diabetic retinopathy and diabetic macular edema, has proven that intelligent diagnostic platforms can be used safely, efficiently and equitably to improve patient outcomes. As it expands into other diagnostic capabilities, Digital Diagnostics has paved the way for automated diagnosis to become a new standard of care that will contribute significantly to democratizing healthcare. Digital Diagnostics is hiring! Learn more about our featured roles and other open positions here: www.digitaldiagnostics.com/careers/
$75M sweet spot round size
2010
$75M
from 2 investors over 1 rounds
Digital Diagnostics raised $75M on September 23, 2022
Investors: Kohlberg Kravis Roberts and + 7 Other investors